• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Indian commentary on the 2009 KDIGO clinical practice guideline for the diagnosis, evaluation, and treatment of chronic kidney disease-mineral and bone disorders.印度对2009年改善全球肾脏病预后组织(KDIGO)慢性肾脏病-矿物质和骨异常诊断、评估及治疗临床实践指南的评论
Indian J Nephrol. 2011 Jul;21(3):143-51. doi: 10.4103/0971-4065.83930.
2
KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).KDIGO 美国评论:2017 年 KDIGO 慢性肾脏病-矿物质和骨异常(CKD-MBD)诊治临床实践指南更新。
Am J Kidney Dis. 2017 Dec;70(6):737-751. doi: 10.1053/j.ajkd.2017.07.019. Epub 2017 Sep 21.
3
KDOQI US commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD-Mineral and Bone Disorder (CKD-MBD).KDIGO 美国评论:2009 年 KDIGO 慢性肾脏病-矿物质和骨异常(CKD-MBD)诊断、评估和治疗临床实践指南。
Am J Kidney Dis. 2010 May;55(5):773-99. doi: 10.1053/j.ajkd.2010.02.340. Epub 2010 Apr 3.
4
Adaptation and implementation of the "Kidney Disease: Improving Global Outcomes (KDIGO)" guidelines for evaluation and management of mineral and bone disorders in chronic kidney disease for practice in the Middle East countries.《改善全球肾脏病预后组织(KDIGO)慢性肾脏病矿物质和骨异常评估与管理指南》在中东国家实践中的适应性与实施情况
Saudi J Kidney Dis Transpl. 2014 Jan;25(1):133-48. doi: 10.4103/1319-2442.124536.
5
KDOQI US commentary on the 2013 KDIGO Clinical Practice Guideline for Lipid Management in CKD.KDIGO 美国专家组关于 2013 年改善全球肾脏病预后组织(KDIGO)慢性肾脏病血脂管理临床实践指南的解读。
Am J Kidney Dis. 2015 Mar;65(3):354-66. doi: 10.1053/j.ajkd.2014.10.005. Epub 2014 Nov 18.
6
KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD.KDIGO 美国评论:2012 年 KDIGO 慢性肾脏病评估与管理临床实践指南
Am J Kidney Dis. 2014 May;63(5):713-35. doi: 10.1053/j.ajkd.2014.01.416. Epub 2014 Mar 16.
7
Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guidelines: a European Renal Best Practice (ERBP) commentary statement.《KDIGO 慢性肾脏病-矿物质和骨异常(CKD-MBD)指南的推荐:欧洲肾脏最佳实践(ERBP)评论声明》
Nephrol Dial Transplant. 2010 Dec;25(12):3823-31. doi: 10.1093/ndt/gfq513. Epub 2010 Sep 9.
8
Canadian Society of Nephrology Commentary on the Kidney Disease Improving Global Outcomes 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder.加拿大肾脏病学会对改善全球肾脏病预后组织(KDIGO)2017年慢性肾脏病-矿物质和骨异常诊断、评估、预防及治疗临床实践指南更新的评论
Can J Kidney Health Dis. 2020 Aug 4;7:2054358120944271. doi: 10.1177/2054358120944271. eCollection 2020.
9
2017 Kidney Disease: Improving Global Outcomes (KDIGO) Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update Implementation: Asia Summit Conference Report.2017年改善全球肾脏病预后组织(KDIGO)慢性肾脏病-矿物质和骨异常(CKD-MBD)指南更新实施:亚洲峰会会议报告
Kidney Int Rep. 2019 Sep 23;4(11):1523-1537. doi: 10.1016/j.ekir.2019.09.007. eCollection 2019 Nov.
10
KDOQI US Commentary on the 2021 KDIGO Clinical Practice Guideline for the Management of Blood Pressure in CKD.KDIGO 美国专家组关于 2021 年改善慢性肾脏病患者血压管理的临床实践指南的解读。
Am J Kidney Dis. 2022 Mar;79(3):311-327. doi: 10.1053/j.ajkd.2021.09.013. Epub 2022 Jan 18.

引用本文的文献

1
KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention and Prevention of Chronic Kidney Disease-Mineral and Bone Disorder (CKDMBD): Indian Commentary.KDIGO 2017慢性肾脏病-矿物质和骨异常(CKDMBD)诊断、评估、预防及防治临床实践指南更新:印度评论
Indian J Nephrol. 2020 Jul-Aug;30(4):221-233. doi: 10.4103/ijn.IJN_1_20. Epub 2020 Jul 30.
2
Prevalence and severity of disordered mineral metabolism in patients with chronic kidney disease: A study from a tertiary care hospital in India.慢性肾脏病患者矿物质代谢紊乱的患病率及严重程度:一项来自印度一家三级护理医院的研究。
Indian J Endocrinol Metab. 2016 Jul-Aug;20(4):460-7. doi: 10.4103/2230-8210.183457.

本文引用的文献

1
Bone mineral density in patients with end-stage renal disease and its evolution after kidney transplantation.终末期肾病患者的骨矿物质密度及其肾移植后的变化
Indian J Nephrol. 2011 Apr;21(2):85-9. doi: 10.4103/0971-4065.82140.
2
KDIGO CKD-MBD Discussion forum: the Brazilian perspective.改善全球肾脏病预后组织慢性肾脏病-矿物质和骨异常讨论论坛:巴西视角
J Bras Nefrol. 2010 Jul-Sep;32(3):229-36.
3
Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guidelines: a European Renal Best Practice (ERBP) commentary statement.《KDIGO 慢性肾脏病-矿物质和骨异常(CKD-MBD)指南的推荐:欧洲肾脏最佳实践(ERBP)评论声明》
Nephrol Dial Transplant. 2010 Dec;25(12):3823-31. doi: 10.1093/ndt/gfq513. Epub 2010 Sep 9.
4
[CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). KDIGO CKD-MBD Clinical Practice Guideline].[慢性肾脏病-矿物质和骨异常(CKD-MBD)。KDIGO慢性肾脏病-矿物质和骨异常临床实践指南]
Clin Calcium. 2010 Jul;20(7):1021-7.
5
Canadian Society of Nephrology commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD-Mineral and Bone Disorder (CKD-MBD).加拿大肾脏病学会对2009年改善全球肾脏病预后组织(KDIGO)慢性肾脏病-矿物质和骨异常(CKD-MBD)诊断、评估及治疗临床实践指南的评论。
Am J Kidney Dis. 2010 May;55(5):800-12. doi: 10.1053/j.ajkd.2010.02.339.
6
[The French clinician's guide to the Kidney disease: Improving global outcomes (KDIGO) for chronic kidney disease-mineral and bone disorders (CKD-MBD)].[法国临床医生慢性肾脏病矿物质和骨异常(CKD-MBD)改善全球肾脏病预后组织(KDIGO)指南]
Nephrol Ther. 2010 Jun;6(3):151-7. doi: 10.1016/j.nephro.2009.12.003. Epub 2010 Apr 15.
7
KDOQI US commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD-Mineral and Bone Disorder (CKD-MBD).KDIGO 美国评论:2009 年 KDIGO 慢性肾脏病-矿物质和骨异常(CKD-MBD)诊断、评估和治疗临床实践指南。
Am J Kidney Dis. 2010 May;55(5):773-99. doi: 10.1053/j.ajkd.2010.02.340. Epub 2010 Apr 3.
8
KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).改善全球肾脏病预后组织(KDIGO)慢性肾脏病-矿物质和骨异常(CKD-MBD)诊断、评估、预防及治疗临床实践指南。
Kidney Int Suppl. 2009 Aug(113):S1-130. doi: 10.1038/ki.2009.188.
9
High prevalence of vitamin D deficiency in north Indian adults is exacerbated in those with chronic kidney disease.北印度成年人维生素D缺乏的高患病率在患有慢性肾病的人群中更为严重。
Nephrology (Carlton). 2009 Apr;14(3):345-9. doi: 10.1111/j.1440-1797.2008.01082.x. Epub 2009 Jan 21.
10
Parathyroid hormone and biochemical profile in chronic kidney disease patients in South India.南印度慢性肾脏病患者的甲状旁腺激素与生化指标
Hemodial Int. 2005 Jan;9(1):63-7. doi: 10.1111/j.1492-7535.2005.01119.x.

印度对2009年改善全球肾脏病预后组织(KDIGO)慢性肾脏病-矿物质和骨异常诊断、评估及治疗临床实践指南的评论

Indian commentary on the 2009 KDIGO clinical practice guideline for the diagnosis, evaluation, and treatment of chronic kidney disease-mineral and bone disorders.

作者信息

Jha V, Kher V, Pisharody R, Sharma R K, Abraham G, Almeida A, Gupta A

机构信息

Postgraduate Institute of Medical Education and Research, Chandigarh, India.

出版信息

Indian J Nephrol. 2011 Jul;21(3):143-51. doi: 10.4103/0971-4065.83930.

DOI:10.4103/0971-4065.83930
PMID:21886971
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3161429/
Abstract

THIS COMMENTARY PRESENTS THE VIEW OF AN EXPERT GROUP OF INDIAN NEPHROLOGISTS ON ADAPTATION AND IMPLEMENTATION OF THE KIDNEY DISEASE

Improving Global Outcomes (KDIGO) guidelines for evaluation and management of mineral and bone disorder in chronic kidney disease (CKD-MBD) for practice in India. Zonal meetings of nephrologists drawn from the cross-section were convened to discuss the KDIGO guidelines. Recommendations were presented in a central meeting of zonal representatives. The finalized recommendations were reviewed by all the participants. There was a broad agreement on most of the recommendations made by the KDIGO workgroup. Significant departures in the current guidelines from the previous Kidney Disease Outcome Quality Initiative (KDOQI) guidelines were also noted. The participants agreed that the available evidence did not allow more precise recommendations, and the recommended best practice suggestions were often based on relatively weak evidence. There is a remarkable lack of data from Indian patients. We comment on specific areas and amplify certain concepts where we feel that further guidance that goes beyond what is stated in the document might help Indian nephrologists in appropriate implementation of the KDIGO guidelines. This commentary is intended to help define practically implementable best practices based on current disease concepts and available research evidence, thereby positively affecting the quality of management of CKD-MBD in India, and eventually improving patient outcomes.

摘要

本评论文章介绍了一个印度肾脏病专家小组对于在印度实施《改善全球肾脏病预后(KDIGO)慢性肾脏病矿物质和骨异常诊治指南》(CKD-MBD)的看法。来自不同地区的肾脏病专家召开了区域会议,讨论KDIGO指南。区域代表在一次中央会议上提出了建议。最终确定的建议由所有参与者进行了审核。与会者对KDIGO工作组提出的大多数建议达成了广泛共识。同时也指出了当前指南与先前的《肾脏病预后质量倡议(KDOQI)指南》存在的重大差异。与会者一致认为,现有证据不足以给出更精确的建议,推荐的最佳实践建议往往基于相对薄弱的证据。印度患者的数据明显匮乏。我们对特定领域进行评论,并对某些概念进行详细阐述,我们认为,超出文件所述内容的进一步指导可能有助于印度肾脏病专家正确实施KDIGO指南。本评论旨在根据当前疾病概念和现有研究证据,帮助确定切实可行的最佳实践,从而对印度CKD-MBD的管理质量产生积极影响,并最终改善患者预后。